Danish biotech Genmab revealed plans to acquire Dutch company Merus in an $8 billion cash deal, representing a 41% premium on Merus’s stock price. Merus’s lead asset is petosemtamab, a bispecific antibody showing promising survival benefits in combination with Keytruda in head and neck cancer patients, currently in pivotal Phase 3 trials. This acquisition aims to strengthen Genmab’s oncology pipeline with a late-stage asset poised for regulatory approval and commercialization, signaling significant consolidation in the bispecific antibody space.